Intracutaneous Reactivity Testing for Medical Devices: Standards, Methods, and Biological Evaluation

Intracutaneous reactivity testing is an essential biocompatibility test that evaluates the localized irritation potential of medical device extracts following intradermal injection into laboratory animals. Performed in accordance with ISO 10993-10 and the equivalent Chinese standard GB/T 16886.10, this test is a fundamental requirement for the biological safety evaluation of medical devices intended to contact skin, mucous membranes, or breached body surfaces. This article provides a comprehensive technical overview of the testing principle, sample requirements, test methodology, scoring criteria, and typical applications of the intracutaneous reactivity test.

Technical Overview

The intracutaneous (intradermal) reactivity test is an in vivo biocompatibility assay designed to assess whether extracts from a medical device or biomaterial produce localized irritation or inflammatory responses when injected into the skin. It is one of the core endpoints of the biological evaluation program described in ISO 10993-1, and it is specifically governed by ISO 10993-10, Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization. In China, the equivalent national standard GB/T 16886.10 applies and is widely referenced in regulatory submissions.

The test principle involves preparing polar and non-polar extracts of the test article according to ISO 10993-12, injecting small volumes of each extract intradermally into the clipped dorsal skin of rabbits, and subsequently scoring the injection sites for erythema (redness) and edema (swelling) at defined observation intervals. The reaction scores of the test extract sites are compared with those of the corresponding solvent control sites to determine whether the device extract possesses irritant properties.

Compared with other irritation models such as the skin patch test or mucosal irritation test, the intracutaneous route bypasses the natural barrier function of intact skin or mucosa. This makes the test more sensitive and allows the detection of potentially irritating leachable substances that might otherwise not produce a response under normal use conditions. For this reason, regulatory authorities in most major markets, including China, the United States, and the European Union, accept data from this test as part of the biological safety documentation for device registration.

Testing Samples

Finished Medical Devices

Complete devices or device components that are intended for clinical use can be subjected to intracutaneous reactivity testing. This category includes surface-contacting devices (such as wound dressings, adhesive bandages, electrodes, and compression garments), external communicating devices (such as catheters, infusion sets, tubing, laparoscopes, and dental materials), and implantable devices whose materials release potentially irritating substances. Testing the finished device in its final form, including any sterilization processing, provides the most representative evaluation of the product as delivered to the patient.

Polymeric, Metallic, and Ceramic Materials

In addition to finished products, raw materials and candidate biomaterials are frequently evaluated. Novel polymers, elastomers, coatings, adhesives, colorants, and additive manufacturing feedstocks may be screened during the design phase to identify irritation hazards before device assembly. Material-level testing is particularly valuable during the research and development stage, when comparing alternative suppliers or formulation changes.

Sample Preparation and Extraction

Test samples are prepared in accordance with ISO 10993-12. When the device cannot be tested as received, extracts are generated using both a polar solvent (commonly 0.9% sodium chloride injection or culture medium) and a non-polar solvent (typically a pharmacopoeial-grade vegetable oil such as sesame or cottonseed oil). Standard extraction conditions include 37 °C for 24 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour, with the condition selected based on the thermal tolerance of the material and the clinical use scenario. The extraction ratio (surface area to solvent volume or mass to solvent volume) must be justified and documented to ensure a sufficiently rigorous challenge.

Testing Items

The intracutaneous reactivity test evaluates the following scored endpoints at each injection site:

• Erythema and eschar formation, graded on a numerical scale from 0 (no reaction) to 4 (severe erythema with slight eschar formation)
• Edema, graded from 0 (no swelling) to 4 (severe swelling extending beyond the raised area)
• Aggregate irritation scores for each animal at each observation time point, calculated by summing the erythema and edema grades
• Primary Irritation Index (PII) or the equivalent integrated scoring, derived from the combined observations across animals and time points
• Comparison of test extract scores against corresponding vehicle control scores to determine whether the reaction exceeds the acceptance threshold

Under the ISO 10993-10 rabbit intracutaneous test, the test article is considered to meet the requirement if the difference between the mean scores of the test sites and the control sites does not exceed 1.0. Any persistent or unusually severe reaction triggers further investigation, possibly including histopathological examination of the injection sites.

Testing Methods

Test System and Animal Welfare

The standard test system is the healthy adult albino rabbit (typically New Zealand White), with a minimum of three animals per test. Animals are acclimatized before the study, and the dorsal area on both sides of the spine is clipped free of fur approximately 24 hours before injection. The study must be conducted under an institutionally approved animal care and use program, and the design should apply the principles of replacement, reduction, and refinement (the 3Rs) to minimize animal use whenever scientifically justified.

Injection Procedure

On the day of treatment, a series of intradermal injections is administered on one side of each rabbit: typically 0.2 mL of the test extract (polar) at two sites, 0.2 mL of the polar control at two sites, 0.2 mL of the test extract (non-polar) at two sites, and 0.2 mL of the non-polar control at two sites. The arrangement may be mirrored on the contralateral side depending on the study design. Intradermal placement is confirmed by the formation of a characteristic bleb at each injection point.

Observation and Scoring

Injection sites are observed and scored for erythema and edema at 24 hours, 48 hours, and 72 hours after injection, with additional observations at 72 hours if reactions persist. Scoring is performed by trained personnel using the standardized grading scales defined in ISO 10993-10. Descriptions of each site should be recorded, and photographic documentation is recommended to support the final evaluation. Scoring is conducted without knowledge of the treatment allocation whenever possible to reduce observer bias.

Interpretation of Results

The maximum difference between the summed test and control scores for each animal and time point is calculated for both the polar and non-polar extracts. If the mean difference across animals does not exceed the threshold specified in the standard, the device is considered non-irritant by the intracutaneous route. If a positive reaction is observed, a confirmatory assessment, chemical characterization of the leachables, or a material modification program may be required to identify and control the source of irritation.

Applications

Intracutaneous reactivity testing supports a wide range of regulatory and engineering objectives throughout the medical device lifecycle:

• Biological safety evaluation and risk management documentation required for registration dossiers submitted to regulatory authorities in China, the United States, the European Union, and other jurisdictions
• Verification of biocompatibility after changes in materials, suppliers, manufacturing processes, sterilization methods, or packaging that could affect leachable profiles
• Pre-market screening of new biomaterials, coatings, adhesives, and polymer formulations during product development
• Support for biological evaluation reports and toxicological risk assessments prepared under the ISO 10993-1 framework
• Evaluation of devices with limited contact duration where irritation is a primary safety concern, such as topical devices, catheters, wound care products, and monitoring accessories
• Equivalence justification and literature-based evaluation strategies, where new test data can supplement existing evidence when material or use changes occur

The test is also referenced by related methods such as ASTM F749, which describes the practice for evaluating material extracts by intracutaneous injection in the rabbit and is commonly applied in North American regulatory contexts.

FAQ

When is intracutaneous reactivity testing required?

The test is generally expected for medical devices that contact skin, mucous membranes, or breached surfaces, as well as external communicating and implantable devices for which irritation is a relevant endpoint under the ISO 10993-1 categorization. The exact requirement depends on the nature, duration, and route of body contact established during the biological evaluation plan.

Can the test be waived if skin irritation testing has already been performed?

Yes, in certain cases. ISO 10993-10 and its related guidance indicate that where valid dermal irritation data already exist for the same extract and test conditions, an additional intracutaneous test may not be necessary. Any waiver must be scientifically justified and documented within the biological evaluation report, and accredited third-party laboratories can assist in preparing such justifications.

Which solvents are used for extraction?

A polar solvent such as 0.9% sodium chloride solution and a non-polar solvent such as pharmacopoeial-grade vegetable oil are used to simulate aqueous and lipid-based tissue environments, ensuring that both hydrophilic and lipophilic leachables are captured in the evaluation.

How many animals are involved, and what happens to them?

The standard design uses three rabbits per test article. Animal welfare is protected by strict ethical review, minimal injection volumes, and humane endpoints; reactions are limited to localized, transient skin responses that are closely monitored by veterinary staff.

How long does the test take?

Following sample receipt and extraction (which may take 24 to 72 hours depending on the selected condition), the in-life phase lasts approximately three to four days including the 72-hour observation period, with an additional interval required for report preparation. The overall turnaround, including protocol review, is typically within a few weeks.

What sample quantity is needed?

The required quantity depends on the surface area or mass to solvent volume ratio defined in ISO 10993-12 and the dimensions of the device. Sponsors should confirm the exact sample amount and shipping arrangement with the testing laboratory in advance, and sterile samples should be delivered in their final packaging to preserve the representative condition.

What does a failed result mean for the product?

A positive irritant response indicates that leachable substances in the extract can provoke local inflammation. Manufacturers should then perform extractable and leachable chemical characterization, identify the causative agent, and consider material substitution, process optimization, or additional rinsing and purification steps before retesting.